BridgeMD
New treatment option for Multimorbidity
Official title Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
ClinicalTrials.gov ID: NCT06431932
What this study is testing
What is Fisetin?
Fisetin is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for multimorbidity.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 and older. Healthy volunteers may be eligible.
You may be able to join if
- Healthy volunteers:
- Aged 20-35 years
- suPAR levels \<3.5 ng/mL (± 15% corresponding to assay variation)
- Able to cooperate cognitively
- Able to read and understand Danish
You likely can't join if
- Body weight \>100 kg
- Inability to swallow pills
- Pregnant and/or lactating
- Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules
- Presence of any condition that the investigator believes would put the subject at risk or would preclude the participant from successfully completing...
- Presence of known chronic diagnosis
See the full eligibility criteria
- Healthy volunteers:
- Aged 20-35 years
- suPAR levels \<3.5 ng/mL (± 15% corresponding to assay variation)
- Able to cooperate cognitively
- Able to read and understand Danish
- Women of childbearing potential must use effective contraception
- Body weight \>100 kg
- Inability to swallow pills
- Pregnant and/or lactating
- Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules
- Presence of any condition that the investigator believes would put the subject at risk or would preclude the participant from successfully completing all aspects of the trial
- Presence of known chronic diagnosis
- Active acute illness
- Prescribed medication, except contraceptives
- Previous cancer diagnosis or treatment
- Use of senolytic and other "anti-aging" supplements Older patients with multimorbidity: Inclusion Criteria: At screening #1 during hospital admission:
- Acutely hospitalized medical patient
- Age ≥65 years
- suPAR \>5 ng/mL (± 15% corresponding to assay variation)
- Multimorbidity (≥2 chronic diagnoses)
- Able to cooperate cognitively
- Able to read and understand Danish At screening #2 28 days after hospital discharge:
- suPAR \>5 ng/mL (± 15% corresponding to assay variation) Exclusion Criteria: At screening #1 during hospital admission:
- Body weight \>100 kg
- Inability to swallow pills
- Known human immunodeficiency virus infection, active hepatitis B or C infection, invasive fungal infection
- Uncontrolled (as per clinical judgment) pleural/pericardial effusions or ascites
- New/active invasive cancer except non-melanoma skin cancers
- Active cancer treatment or disseminated cancer
- Known condition associated with major immunodeficiency
- Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules
- Use of senolytic and other "anti-aging" supplements At screening #2 28 days after hospital discharge:
- Body weight \>100 kg
- CRP \>30 mg/L (± 15% corresponding to assay variation)
- Inability to swallow pills
- Presence of any condition, or abnormal routine biochemistry test, that the investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial
- Unstable (as per clinical judgment) major disorders, e.g., cardiovascular, renal, endocrine, immunological, hepatic disorder, or cancer
- Estimated glomerular filtration rate (eGFR) \<15 ml/min/1.73 m2 or as per clinical judgment (e.g., risk of acute kidney injury)
- Human immunodeficiency virus infection, known active hepatitis B or C infection, invasive fungal infection
- Uncontrolled (as per clinical judgment) pleural/pericardial effusions or ascites
- New/active invasive cancer except non-melanoma skin cancers
- Active cancer treatment or disseminated cancer
- Known condition associated with major immunodeficiency
- Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules
- people taking strong inhibitors or inducers of CYP3A4 or as per clinical judgment
- people taking specified substrates with a narrow therapeutic range for CYP3A4 or as per clinical judgment
- people taking specified inhibitors, inducers, or substrates of CYP2D6, CYP2C9, or CYP2C8, or as per clinical judgment
- people regularly using drug classes or specific medications or as per clinical judgment
- Use of senolytic and other "anti-aging" supplements
The study team makes the final eligibility decision.
Where it's taking place
- Hvidovre, Denmark
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hvidovre, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.